Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects

Trial Profile

An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs Ilodecakin (Primary)
  • Indications Breast cancer; Colorectal cancer; Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Acronyms Willow II
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 22 May 2018 Status changed from active, no longer recruiting to completed.
    • 27 Mar 2018 Planned End Date changed from 9 Mar 2018 to 9 Apr 2018.
    • 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top